Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 5-UK first to roll out AstraZeneca shots in race to stem COVID surge

Mon, 04th Jan 2021 07:57

* UK first to roll out AstraZeneca vaccine

* 82-year-old dialysis patient is first to get vaccine

* UK hails British scientific 'triumph'

* Johnson mulls tougher lockdown in England

* Concerns grow over South African variant
(Writes through)

By Guy Faulconbridge and Alistair Smout

LONDON, Jan 4 (Reuters) - Britain began vaccinating its
population with Oxford University and AstraZeneca's
COVID-19 shot on Monday in a world first, racing to give
protection to the elderly and vulnerable as a new surge of cases
threatened to overwhelm hospitals.

Britain touted a scientific "triumph" that puts it at the
vanguard of the West as dialysis patient Brian Pinker, 82,
became the first person to get the Oxford/AstraZeneca shot
outside of a trial.

As major powers eye the benefits of being first out of the
pandemic, Britain is rushing to vaccinate its population faster
than the United States and the rest of Europe, though Russia and
China have been inoculating their citizens for months.

Just under a month since Britain became the first country in
the world to roll out the vaccine developed by Pfizer
and Germany's BioNTech, Pinker, who has kidney disease, received
the Oxford/AstraZeneca shot.

"I am so pleased to be getting the COVID vaccine today and
really proud that it is one that was invented in Oxford,"
Pinker, a retired maintenance manager, said just a few hundred
metres from where the vaccine was developed.

Pinker said he was looking forward to celebrating his 48th
wedding anniversary with wife Shirley in February.

Britain, grappling with the world's sixth worst death toll
and one of the worst economic hits from the COVID crisis, has
seen a resurgence in cases to new daily highs.

That has put renewed urgency on rollout plans. Britain is
prioritising getting a first dose of a vaccine to as many people
as possible over giving second doses, despite some doctors and
scientists expressing concern.

Since the rollout of the Pfizer vaccine started on Dec. 8,
Britain has put more than a million COVID-19 vaccines into arms
- more than the rest of Europe put together, Health Secretary
Matt Hancock said.

"That's a triumph of British science that we've managed to
get where we are," Hancock told Sky. "Right at the start, we saw
that the vaccine was the only way out long term."

Prime Minister Boris Johnson’s government has secured 100
million doses of the Oxford/AstraZeneca vaccine which can be
stored at fridge temperatures between two to eight degrees,
making it easier to distribute than the Pfizer shot.

Six hospitals in England are administering the first of
around 530,000 doses Britain has ready. The programme will be
expanded to hundreds of other British sites in coming days, and
the government hopes it will deliver tens of millions of doses
within months.

The U.S. Centers for Disease Control and Prevention said it
had administered 4.2 million first doses of COVID-19 vaccines as
of Saturday morning and distributed 13.07 million doses.

But Israel is the world leader: more than a tenth of its
population have had a vaccine and Israel is now administering
more than 150,000 doses a day.

VACCINE RACE

Britain became the first Western country to approve and roll
out a COVID-19 vaccine. Others have taken a longer and more
cautious approach, though Russia and China have been inoculating
their citizens for months with several different vaccines still
undergoing late-stage trials.

China on Dec. 31. approved its first COVID-19 vaccine for
general public use, a shot developed by an affiliate of
state-backed pharmaceutical giant Sinopharm. The
company said it is 79% effective against the virus.

Russia said on Nov. 24 its Sputnik V vaccine was 91.4%
effective based on interim late-stage trial results. It started
vaccinations in August and has inoculated more than 100,000
people so far.

India approved the Oxford/AstraZeneca vaccine on Sunday for
emergency use.

Two new variants of the coronavirus are complicating the
COVID-19 response and might force new national restrictions in
England.

Scientists are not fully confident that COVID-19 vaccines
will work on a variant found in South Africa, ITV political
editor Robert Peston said.

Cases have also been fuelled by a highly transmissible UK
variant and more than 75,000 people in the United Kingdom have
died from COVID within 28 days of a positive test.

Johnson said on Sunday that tougher restrictions were
likely, even with millions already living under the strictest
tier of rules.

England is divided into four different tiers, depending on
the prevalence of the virus, and Hancock said the rules in some
parts of the country in Tier 3 were clearly not working.

Asked whether the government was considering imposing a new
national lockdown, Hancock said: "We don't rule anything out."

Andrew Pollard, the head of the Oxford Vaccine Group, also
received the vaccine on Monday.

"We are at the point of being overwhelmed by this disease,"
he told BBC TV. "I think it (the vaccine) gives us a bit of
hope, but I think we've got some tough weeks ahead."
(Writing by William James, Guy Faulconbridge and Alistair
Smout; Editing by Susan Fenton, Kate Holton, Raissa Kasolowsky
and Nick Macfie)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.